Literature DB >> 8837575

Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension.

M Testa1, M Yeh, P Lee, R Fanelli, F Loperfido, J W Berman, T H LeJemtel.   

Abstract

OBJECTIVES: This study sought to determine the circulating levels of cytokines and their respective endogenous modulators in patients with congestive heart failure of variable severity.
BACKGROUND: Activation of immune elements localized in the heart or periphery, or both, may promote release of cytokines in patients with congestive heart failure. Although an increased circulating level of tumor necrosis factor-alpha (TNF-alpha) and its soluble receptor type II (sTNF-RII) is well documented, less is known about other cytokines (i.e., interleukin-1-beta [IL-1-beta], interleukin-6 [IL-6] and interleukin-2 [IL-2] and their soluble receptor/receptor antagonists).
METHODS: Circulating levels of TNF-alpha and sTNF-RII, IL-1-beta, IL-1 receptor antagonist (IL-1-Ra), IL-6, IL-6 soluble receptor (IL-6-sR), IL-2 and IL-2 soluble receptor-alpha were measured using enzyme-linked immunosorbent assay kits (Quantikine, R&D Systems) in 80 patients with congestive heart failure due to coronary artery disease or hypertension. The severity of their symptoms, which ranged from New York Heart Association functional class I to IV, was confirmed by measurement of peak oxygen consumption.
RESULTS: The percentage of patients with elevated levels of cytokines and their corresponding soluble receptor/receptor antagonists significantly increased with functional class. For TNF-alpha and IL-1-beta, the percentage of patients with elevated levels of soluble receptor/receptor antagonists was higher than that of patients with elevated levels of the cytokine itself. For IL-6, the percentage of patients with elevated levels of IL-6-sR tended to be lower than that of patients with elevated levels of IL-6. All but two patients had undetectable levels of IL-2, and all but seven had levels of IL-2-sR within a normal range.
CONCLUSIONS: In patients with congestive heart failure, circulating levels of cytokines increased with the severity of symptoms. In these patients, circulating levels of sTNF-RII and IL-1-Ra are more sensitive markers of immune activation than are circulating levels of TNF-alpha and IL-1-beta, respectively. Levels of IL-2 and IL-2-sR are not elevated when congestive heart failure is due to coronary artery disease or hypertension.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8837575     DOI: 10.1016/s0735-1097(96)00268-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  122 in total

Review 1.  The role of anti-cytokine therapy in the failing heart.

Authors:  A Deswal; A Misra; B Bozkurt
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

Review 2.  Activation of cytokines as a mechanism of disease progression in heart failure.

Authors:  B Bozkurt
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 3.  Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation.

Authors:  Weiwei Li; Brian Olshansky
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

Review 4.  Tumor necrosis factor-α, kidney function, and hypertension.

Authors:  Eamonn Mehaffey; Dewan S A Majid
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-19

Review 5.  Right Heart Failure and Cardiorenal Syndrome.

Authors:  Thida Tabucanon; Wai Hong Wilson Tang
Journal:  Cardiol Clin       Date:  2020-03-02       Impact factor: 2.213

6.  Effects of ischemic preconditioning on myocardium Caspase-3, SOCS-1, SOCS-3, TNF-α and IL-6 mRNA expression levels in myocardium IR rats.

Authors:  Jiangwei Ma; Zengyong Qiao; Biao Xu
Journal:  Mol Biol Rep       Date:  2013-10-05       Impact factor: 2.316

7.  Prognostic significance of biomarkers in predicting outcome in patients with coronary artery disease and left ventricular dysfunction: results of the biomarker substudy of the Surgical Treatment for Ischemic Heart Failure trials.

Authors:  Arthur M Feldman; Douglas L Mann; Lilin She; Michael R Bristow; Alan S Maisel; Dennis M McNamara; Ryan Walsh; Dorellyn L Lee; Stanislaw Wos; Irene Lang; Gretchen Wells; Mark H Drazner; John F Schmedtje; Daniel F Pauly; Carla A Sueta; Michael Di Maio; Irving L Kron; Eric J Velazquez; Kerry L Lee
Journal:  Circ Heart Fail       Date:  2013-04-12       Impact factor: 8.790

8.  Alterations in immunocyte tumor necrosis factor receptor and apoptosis in patients with congestive heart failure.

Authors:  Vishnu K Rumalla; Steve E Calvano; Alan J Spotnitz; Tyrone J Krause; Robert J Hilkert; Edward Lin; Stephen F Lowry
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

9.  Interleukin-1β reduces L-type Ca2+ current through protein kinase Cϵ activation in mouse heart.

Authors:  Nabil El Khoury; Sophie Mathieu; Céline Fiset
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

10.  Sympathoexcitation in response to cardiac and pulmonary afferent stimulation of TRPA1 channels is attenuated in rats with chronic heart failure.

Authors:  Ryan J Adam; Zhiqiu Xia; Kristina Pravoverov; Juan Hong; Adam J Case; Harold D Schultz; Steven J Lisco; Irving H Zucker; Han-Jun Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-01       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.